Reyvow (lasmiditan) NDC 0002-4491

NDC codes

FDA NDC Directory

Product NDC (as listed)0002-4491Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00002-4491Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0002-4491-08	00002449108	2 BLISTER PACK in 1 CARTON (0002-4491-08) / 4 TABLET in 1 BLISTER PACKMarketed from Jan 31, 2020
0002-4491-62	00002449162	1 BLISTER PACK in 1 CARTON (0002-4491-62) / 2 TABLET in 1 BLISTER PACKMarketed from Feb 28, 2022 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Reyvow
Generic name (nonproprietary): lasmiditan
Active ingredients: Lasmiditan — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Eli Lilly and Company
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211280
Marketing start: Oct 11, 2019
Marketing end: Feb 21, 2027
DEA schedule: CV
Identifiers: Product ID 0002-4491_29f467c6-0365-4831-b4ce-9a0eefaf5896SPL ID 29f467c6-0365-4831-b4ce-9a0eefaf5896SPL set ID aea3358c-ff41-4490-9e6d-c7bf7b3de13fRxCUI 2256937, 2256943, 2256945, 2256947UNII 760I9WM792UPC 0300024491083

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400002449108 followed by a unit qualifier and the quantity

Package 00002-4491-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2026.

Indications (excerpt from the label)

REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 211280

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 211280
Product	Strength	Form · route	Labeler	Product NDC
Reyvowlasmiditan	Lasmiditan 50 mg/1	TabletOral	Eli Lilly and Company	0002-4312